Study tumor biomarkers in recurrent metastatic colon cancer
Part of Cancer, Digestive system clinical trials.
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal (colon or rectal) cancer that first returned and spread after your previous surgery
- Your cancer spread is to a single organ/site, and that may be treated with another operation
- Your cancer was diagnosed as adenocarcinoma (a common colon/rectal cancer type) on biopsy or fluid testing
- You are at least 18 years old
- You are expected to live at least 12 weeks
- Your general health/activity level is ECOG 0 to 1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early signs that treatment is not working in people with stage IV colon or rectal cancer that has spread only to the liver. It may help doctors adjust care sooner by using regular blood, stool, and tissue samples around liver procedures.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This study looks at whether a combination of clinical factors and genetic tests can better predict early return of cancer in people who had surgery for colorectal cancer that spread to the liver. It may help guide future treatment decisions.
This study looks at metabolic biomarkers in blood and tumor tissue to help detect colorectal cancer earlier, predict outcomes, and monitor for recurrence. It includes both people newly diagnosed with colorectal cancer and healthy volunteers for comparison.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.